Nektar Therapeutics (NKTR)
74.25
+0.56
(+0.76%)
USD |
NASDAQ |
Aug 25, 14:41
Nektar Therapeutics Shareholders Equity (Quarterly) : 903.12M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 903.12M |
| March 31, 2026 | 576.22M |
| December 31, 2025 | 89.83M |
| September 30, 2025 | 85.09M |
| June 30, 2025 | -24.21M |
| March 31, 2025 | 13.74M |
| December 31, 2024 | 60.74M |
| September 30, 2024 | 48.88M |
| June 30, 2024 | 79.69M |
| March 31, 2024 | 126.70M |
| December 31, 2023 | 130.99M |
| September 30, 2023 | 159.37M |
| June 30, 2023 | 196.96M |
| March 31, 2023 | 240.86M |
| December 31, 2022 | 366.64M |
| September 30, 2022 | 412.22M |
| June 30, 2022 | 458.73M |
| March 31, 2022 | 607.89M |
| December 31, 2021 | 679.51M |
| September 30, 2021 | 801.54M |
| June 30, 2021 | 904.98M |
| March 31, 2021 | 994.51M |
| December 31, 2020 | 1.077B |
| September 30, 2020 | 1.171B |
| June 30, 2020 | 1.256B |
| Date | Value |
|---|---|
| March 31, 2020 | 1.296B |
| December 31, 2019 | 1.405B |
| September 30, 2019 | 1.489B |
| June 30, 2019 | 1.557B |
| March 31, 2019 | 1.634B |
| December 31, 2018 | 1.718B |
| September 30, 2018 | 1.790B |
| June 30, 2018 | 1.860B |
| March 31, 2018 | 58.28M |
| December 31, 2017 | 87.83M |
| September 30, 2017 | 84.16M |
| June 30, 2017 | 3.386M |
| March 31, 2017 | 44.75M |
| December 31, 2016 | 88.12M |
| September 30, 2016 | -67.85M |
| June 30, 2016 | -39.25M |
| March 31, 2016 | -0.275M |
| December 31, 2015 | 6.429M |
| September 30, 2015 | 39.05M |
| June 30, 2015 | 35.10M |
| March 31, 2015 | 77.30M |
| December 31, 2014 | 36.33M |
| September 30, 2014 | 47.22M |
| June 30, 2014 | -35.36M |
| March 31, 2014 | -9.809M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Elite Pharmaceuticals, Inc. | 104.83M |
| Daré Bioscience, Inc. | -0.5601M |
| Aclaris Therapeutics, Inc. | 124.58M |
| Eton Pharmaceuticals, Inc. | 46.58M |
| Journey Medical Corp. | 32.11M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.095B |
| Total Liabilities (Quarterly) | 192.01M |
| Debt to Equity Ratio | 0.1505 |
| Current Ratio | 10.42 |
| Net Debt Paydown Yield | 0.43% |